SEC Company Response from Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE) — Dec 19, 2017
Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: Dec. 19, 2017 · CIK: 0001444192 · Accession: 0001193125-17-373193
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220755
Letter
Re: Acasti Pharma Inc.
December 19, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-1
File No. 333-220755
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acasti Pharma Inc., a Québec corporation (the “Company”) respectfully requests that the Securities and Exchange Commission (the “Commission) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) so that the same will become effective at 4:30 p.m. on December 19, 2017 or as soon thereafter as is practicable.
The Company also requests the Commission confirm the effective date and time of the Registration Statement to Company counsel, Osler, Hoskin & Harcourt LLP, Attention: Jason Comerford, by email to JComerford@osler.com.
ACASTI PHARMA INC.
By:
/s/ Janelle D’Alvise
Name:
Janelle D’Alvise
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 19, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Acasti Pharma Inc. Registration Statement on Form F-1 File No. 333-220755 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acasti Pharma Inc., a Québec corporation (the “Company”) respectfully requests that the Securities and Exchange Commission (the “Commission) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) so that the same will become effective at 4:30 p.m. on December 19, 2017 or as soon thereafter as is practicable. The Company also requests the Commission confirm the effective date and time of the Registration Statement to Company counsel, Osler, Hoskin & Harcourt LLP, Attention: Jason Comerford, by email to JComerford@osler.com. ACASTI PHARMA INC. By: /s/ Janelle D’Alvise Name: Janelle D’Alvise Title: Chief Executive Officer